Modified bacterial cellulose scaffolds for localized doxorubicin release in human colorectal HT-29 cells by Cacicedo, Maximiliano Luis et al.
Accepted Manuscript
Title: Modified bacterial cellulose scaffolds for localized
doxorubicin release in human colorectal HT-29 cells
Author: Maximiliano L. Cacidedo Ignacio E. Leo´n Jimena S.
Gonzalez Luismar M. Porto Vera A. Alvarez Guillermo R.
Castro
PII: S0927-7765(16)30006-6
DOI: http://dx.doi.org/doi:10.1016/j.colsurfb.2016.01.007
Reference: COLSUB 7584
To appear in: Colloids and Surfaces B: Biointerfaces
Received date: 13-9-2015
Revised date: 6-12-2015
Accepted date: 3-1-2016
Please cite this article as:MaximilianoL.Cacidedo, IgnacioE.Leo´n, JimenaS.Gonzalez,
Luismar M.Porto, Vera A.Alvarez, Guillermo R.Castro, Modified bacterial cellulose
scaffolds for localized doxorubicin release in human colorectal HT-29 cells, Colloids
and Surfaces B: Biointerfaces http://dx.doi.org/10.1016/j.colsurfb.2016.01.007
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
1 
 
Modified bacterial cellulose scaffolds for localized doxorubicin release in human 
colorectal HT-29 cells 
 
 
Maximiliano L. Cacicedo1, Ignacio E. León2, Jimena S. Gonzalez3, Luismar M. Porto4, Vera 
A. Alvarez3 and Guillermo R. Castro1 
 
1 Nanobiomaterials Laboratory, Institute of Applied Biotechnology (CINDEFI, UNLP-
CONICET-CCT La Plata), Department of Chemistry, School of Sciences, Universidad 
Nacional de La Plata, Calle 47 y115, CP 1900 La Plata, Argentina. 
 
2 Chemical Inorganic Center (CEQUINOR, UNLP, CONICET), School of Sciences, 
Universidad Nacional de La Plata (UNLP), Calle 47 y 115, (1900) La Plata, Argentina 
 
3 CoMP (Composite Materials Group), Research Institute of Material Science and Technology 
(INTEMA), Engineering School, National University of Mar del Plata,  
Solis 7575, (B7608FDQ) Mar del Plata, Argentina 
 
4 Integrated Technologies Laboratory (InteLAB), CTC/EQA, Universidad Federal de Santa 
Catarina, Florianopolis, Brazil. 
 
 
 
Corresponding Author: Guillermo R. Castro 
E-mail: grcastro@gmail.com 
Phone: ++54.221.4833794 ext. 132 (Office) 
 
 
 
 
 
 
 
2 
 
Graphical abstract 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CO O
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
CO
O
O
O
O
O
O
O
Dox 
Tumor 
BC‐Alg 
Local 
applicati
3 
 
Highlights 
 In-situ modification of bacterial cellulose membranes with alginate was performed. 
 The hybrid bacterial cellulose-alginate membranes are able to control release 
doxorubicin. 
 FTIR, XRD, TGA and SEM of bacterial cellulose-alginate scaffolds showed strong 
interconnected hybrid network with enhanced hydrophilicity. 
 The bacterial cellulose-alginate matrix was able to incorporate from 3.7 μg/g to 11.0 
μg/g doxorubicin/matrix range with linear responses. 
 Brunauer–Emmett–Teller and Barrett–Joyner–Halenda analyses of the bacterial 
cellulose-alginate scaffolds showed an increase of the surface area in about 84% and 
the rise of pore volume for more than 200% compared to BC films. 
 The bacterial cellulose-alginate containing doxorubicin showed high efficiency on 
killing HT-29 human colorectal adenocarcinoma cells compared to free doxorubicin in 
the same range concentrations. 
 
 
Abstract 
Bacterial cellulose (BC) films modified by the in situ method with the addition of alginate (Alg) 
during the microbial cultivation of Gluconacetobacter hansenii under static conditions increased the 
loading of doxorubicin by at least three times. Biophysical analysis of BC-Alg films by scanning 
electron microscopy, thermogravimetry, X-ray diffraction and FTIR showed a highly homogeneous 
interpenetrated network scaffold without changes in the BC crystalline structure but with an increased 
amorphous phase. The main molecular interactions determined by FTIR between both biopolymers 
clearly suggest high compatibility. These results indicate that alginate plays a key role in the 
biophysical properties of the hybrid BC matrix. BC-Alg scaffold analysis by nitrogen adsorption 
isotherms revealed by the Brunauer–Emmett–Teller (BET) method an increase  in surface area  of 
about 84% and in pore volume of more than 200%. The Barrett–Joyner–Halenda (BJH) model also 
showed an increase of about 25% in the pore size compared to the BC film. 
Loading BC-Alg scaffolds with different amounts of doxorubicin decreased the cell viability of HT-29 
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human colorectal adenocarcinoma cell line compared to the free Dox from around 95% to 53% after 
24 h and from 63% to 37% after 48 h. Dox kinetic release from the BC-Alg nanocomposite displayed 
hyperbolic curves related to the different amounts of drug payload and was stable for at least 14 days. 
The results of the BC-Alg nanocomposites show a promissory potential for anticancer therapies of 
solid tumors. 
 
 
Keywords: bacterial cellulose, alginate, drug delivery, nanocomposite, doxorubicin, cancer therapy, 
human colorectal HT-29 cells 
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1. Introduction 
Cancer, one of the leading causes of death worldwide, accounted for 8.2 million diseases in 2012 [1]. 
Typically, cancer arises from a normal cell that undergoes a transformation into an abnormal cell, and 
consequently a malignant tumor develops. Although the choice of drug chemotherapy depends on the 
type of cancer pathology, tumor stage and patient characteristics and tolerance, the surgical resection 
of the tumor is the preferred treatment once cancer has been diagnosed [2]. Nevertheless, chemo- 
and/or radiotherapies are always involved in most types of cancer diseases. In the case of 
chemotherapy, the drugs always show serious limitations severely affecting the patient’s health, 
recovery and quality of life. These limitations may be due to poor drug solubility, high toxicity, 
immune suppression, red blood cell and stem cell depletion, high dosage and nonspecific action [3]. 
Additionally, by intravenous (iv) drug administration, it is very difficult to keep medicine 
concentrations surrounding the tumor microenvironment within the therapeutic window. Besides, the 
chemo-resistance to standard treatments develops in nearly all patients [4]. Therefore, in the 
chemotherapeutic regimens, high iv drug doses are given with the consequent adverse side effects and 
drug accumulation on nontargeted tissues [5]. Among them, doxorubicin (Dox), a member of the 
anthracycline family, is extensively used in anticancer treatments but it causes very well-described 
undesirable side effects such as cardiotoxicity, depletion of red blood cells (anemia), hair loss, 
stomach pain and others  [6]. 
The ability of anticancer drugs to reach the appropriate anatomic region of the body where the 
tumor is located is always relevant and has been the subject of intense research during the last 10 
years. Different new surgical possibilities, pharmaceutical molecules, drug delivery techniques and 
devices, among others, play a major role in the development of novel and personalized cancer 
therapies. Particularly, localized delivery of chemotherapeutic agents may help to achieve better 
results than those of systemic chemotherapy.  In this sense, local application of a drug delivery device 
within a specific zone where cancer cells are proliferating will generate a major exposure of those cells 
to the chemotherapeutic drugs and it may: (i) decrease toxic adverse effects by using lower drug doses; 
(ii) decrease tumor volume more efficiently, increasing surgeons’ possibility to succeed in total tumor 
resection; (iii) enhance the effect of regular chemotherapy in the case of nonviable surgery. Local drug 
delivery is a recent alternative for the therapy of some solid tumors that reduce the chemotherapeutic 
toxicity and can provide better regimens using clinically approved drugs [7]. Also, anticancer 
therapies with local drug delivery could be used in those cases where surgery cannot be an alternative 
or effective without compromising healthy tissues or physiologically functional organs. Another 
option might be the application of the films in order to reduce tumor volume before surgery or as 
adjuvant targeted therapy to prevent tumor recurrence after surgery [8,9].  
Matrices composed of biopolymer blends are promising candidates for the development of local 
drug delivery systems. These polymers have several advantages, such as synthesis methods based on 
Green chemistry, availability in large quantities, and nontoxic properties as they are listed in the  
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GRAS (generally recognized as safe, FDA, US) category, are renewable, easy to handle, 
biodegradable, commercially available and generally of low cost. Among them, alginates are GRAS 
polymers extensively studied for many pharmaceutical and food applications [10]. Alginate is a 
biopolymer composed of guluronic and mannuronic acids produced by algae and some bacteria. 
Alginate is able to cross-link in the presence of polyvalent cations forming stable gels commonly 
named “egg-box” structures. Calcium is the typical cross-linker for biomedical and food industry 
applications because of its lack of toxicity. Previous results in our laboratory demonstrated the 
potential use of alginates in the synthesis of drug delivery devices [11–13]. 
Lately, bacterial cellulose (BC)  has been intensively studied for many industrial applications 
including the biomedical field, such as tissue engineering and drug delivery [14]. BC is an 
extracellular polysaccharide detected in gram-positive and especially in gram-negative bacteria at the  
air/culture media interface. The most efficient cellulose producers are members of the acetic acid 
bacteria, and particularly Gluconacetobacter hansenii has been extensively used as a BC producer 
model. BC is produced in nanofibrils composed of β-1→4 linkages of glucose units stabilized by inter- 
and intrachain hydrogen bridges. In static microbial cultures, the BC nanofibrillar structure is roughly 
10 nm thick and 50 nm wide extremely pure cellulose network showing high water content (more than 
90%), high mechanical strength and well-defined biocompatibility [14]. Native BC presents some 
properties that contribute to making it a good biomaterial to be used as a matrix for localized drug 
delivery. Such properties involve the stability of the material at high temperatures,  facilitating its 
sterilization by autoclaving [15]. Its flexibility and porosity, similar to that of collagen, might be one 
of the reasons  for its well-tolerated biocompatibility [14]. Besides, BC can be purified reaching 
endotoxin values of <20 endotoxin units/device approved by the FDA for implants [16]. However, 
plain BC films are not able to entrap, keep and control the release of Dox. In order to provide the 
properties of drug controlled release, recently a novel strategy for the ex situ modification of native 
bacterial cellulose films was reported [17]. The BC scaffold was modified by an ex situ method with 
the synthesis of CaCO3-carragenaan microparticles containing Dox on the film surface. The CaCO3 
microparticles containing Dox were responsible for the sustained release of the drug and stable on 
shelf for more than one year [17]. Alternatively, BC films could be modified by the in situ method 
consisting in the addition of molecules during the initial stages of bacterial fermentation. When BC 
was reinforced by in situ modification using polymers, such as gelatin, collagen and chitosan for 
biomedical purposes, novel biophysical film properties were found [18]. In this sense, the addition of 
negatively charged polymers such as alginates to bacterial cultures during BC synthesis could enhance 
the interaction between the hybrid films and Dox, as previously reported for the pectin-Dox model 
[19]. Recently, native or chemically modified BC-alginate composites were found to be versatile 
systems for mammalian eukaryotic cell cultivation because of the ductility and functionally of 
nanocellulose-alginate networks [20–22]. Also, BC and alginate were mixed by an ex situ method with 
silver sulfadiazine payload [23]. Additionally, the synthesis of BC nanocomposite in the presence of 
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low sodium alginate concentration (0.04%) by A. xylinum was studied [24].  
In the present study, nanocomposite bacterial cellulose films modified in situ by the addition of 
alginate during the static cultivation of Gluconacetobacter hansenii were produced to formulate 
scaffolds containing doxorubicin for cancer treatment. The nanocomposite films were purified and 
characterized by thermogravimetry (TGA), X-ray diffraction (XRD), infrared spectroscopy (FTIR), 
optical, fluorescence and scanning electron microscopy (SEM), BET-BJH (Brunauer–Emmett–Teller  
and the Barrett–Joyner–Halenda) methods. In addition, Dox loading and drug kinetic release are 
reported. Finally, the effect of Dox release from the BC-alginate nanocomposite films was tested on 
the human colorectal adenocarcinoma cell line (HT-29) in order to test the therapeutic effect in 
comparison to the direct exposure to Dox.  
 
2. Materials and Methods 
2.1. Chemicals and media 
Sodium alginate was purchased from Monsanto Co. Doxorubicin (Dox, MW 579.98) was kindly 
supplied by LKM pharmaceuticals (Argentina). All other reagents used were of analytical or 
microbiological grade and purchased from Sigma-Aldrich (St. Louis, MO) or Merck (Darmstadt, 
Germany) except as otherwise indicated.  
Dox was quantified by spectrofluorimetry (Perkin Elmer LS 50B, Japan) using λexc 476 nm and 
λem 588 nm with appropriate calibration curves.  
Cell culture materials were purchased from Corning (Princeton, NJ, USA), Dulbecco´ s Modified 
Eagles Medium (DMEM), TrypLETM from Gibco (Gaithersburg, MD, USA), and fetal bovine serum 
(FBS) from Internegocios SA (Argentina). All other chemicals were from Sigma Chemical Co. (ST. 
Louis, MO). 
2.2. Microbial cellulose production with sodium alginate addition 
Bacterial cellulose was synthesized by Gluconacetobacter hansenii (ATCC 23769) grown statically in 
the following medium, in g l-1: 25.0 manitol, 5.0 yeast extract, 3.0 peptone. Sodium alginate was added 
at concentrations of 1.0%. The pH media was adjusted to 6.5 with 0.1M NaOH solution before 
sterilization. The culture was kept statically in 96-well plates at 27°C for 14 days.  
2.3. Microbial cellulose purification  
Native cellulose and hybrid cellulose films were collected from the plates for the purification process 
and washed three times with a 70% ethanol solution for 60 min. Later, the purification was performed 
using 70% ethanol/0.1 N NaOH solution for 24 h at 30ºC. After that, repetitive washes with 70% 
ethanol were done until neutral pH was reached. Finally, the films were exposed to a solution of 70% 
ethanol/ 0.5M CaCl2, in order to achieve ionic gelation of the alginate remaining inside the cellulose.  
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2.4. Biomaterial characterization 
2.4.1. Thermogravimetric analysis (TGA) 
Dynamic thermogravimetric measurements of native and hybrid bacterial cellulose membranes were 
performed by using a Shimadzu TGA-50 instrument. Tests were run from 20ºC to 900ºC at a heating 
rate of 10ºC/min under N2 atmosphere. 
2.4.2. X-ray diffraction (XRD) 
XRD patterns of cellulose film samples were collected in reflection mode on a glass substrate. The 
measurement was performed with an Analytical Expert instrument using Cu-Kα radiation (λ= 1.54 Å) 
from 2θ= 10 to 70º in continuous mode with 0.07º step size. The results were analyzed using Origin 
software. 
2.4.3. Fourier transform infrared spectroscopy (FTIR) 
The FTIR spectra of the lyophilized samples were recorded in a spectrometer (Thermo Scientific 
Nicolet, 6700 model, CT, USA) coupled with an ATR (attenuated total reflectance) accessory for all 
measurements. A number of 32 scans were performed for each sample in the 600 to 4,000 cm−1 range 
and resolution of 4 cm-1. 
2.4.4. Scanning electron microscopy (SEM) 
Samples were firstly dried by the critic point technique. After that,  the surface was sputtered with 
gold using a metalizer (Balzers SCD 030), obtaining a layer thickness between 15 and 20 nm. Film 
surfaces and morphologies were observed by SEM (Philips SEM 505 model, Rochester, NY, USA), 
and the images were processed by an image digitizer program (Soft Imaging System ADDA II). 
2.4.5. Roughness analysis 
SEM images were analyzed by ImageJ software (NIH, USA). The roughness of the surface was 
reflected by the standard variation of the gray values of all the pixels on the image. First, the SEM 
image files were opened by the software and converted to an 8-bit image. Then, all the pixels on the 
image were selected and statistically measured by a computer equipped with the software. The less the 
standard variation value is, the smoother the surface is. Histograms of SEM images at 1000x 
magnification were performed. 
2.4.6. Optical and fluorescence microscopy 
Drug loaded hybrid films were placed on 48-well plates with the same media and conditions as those 
of cell culture assays. Also, free Dox was used in the same concentration range used for cell cultures. 
After 24 and 48 h a sample was taken from each well and analyzed by microscopy. Optical and 
fluorescence microscopy was carried out in Leica DM 2500 microscope (Wetzlar, Germany) equipped 
with filter N2.1 for excitation in the green zone. Excitation filter BP: 515-560 nm, monochromatic 
mirror: 580nm, suppressor filter LP: 590nm.   
2.4.7. Nitrogen adsorption isotherms (BET) 
Nitrogen adsorption–desorption at 77 K at a bath temperature of −195.8 ・C was carried out for dry 
native and hybrid cellulose films. The surface area, pore volume and pore size of both membranes 
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were calculated with Micromeritics ASAP 2020 V3.00 software using the Brunauer–Emmett–Teller 
(BET) equation and the Barrett–Joyner–Halenda (BJH) method. 
2.5. Doxorubicin loading studies 
BC systems were immersed in Dox solutions with 3.7 µmols to 11.0 µmols in ethanol 80% solution 
and stirred at 230 rpm, at 25 °C for 20 h. The pH was measured before and after the procedure; no 
change was observed (pH= 7.0). The membranes were taken out from the vials and residual Dox was 
spectrofluorometrically assayed in the supernatants [17]. Membranes were washed one time in ethanol 
80% and later in physiologic solution for 10 min. The loading efficiency was evaluated as follows: 
Dox incorporation = 
(DoxI - DoxS) 
WBC 
 
Where DoxI are the µmols of doxorubicin at time zero, DoxS are the µmols of doxorubicin in the 
supernatant and WBC is the mass of the BC film (grams). 
Control assays without membranes were performed. Neither Dox degradation, nor fluorescence 
maximum shift or intensity decrease were observed after the encapsulation procedure.  
2.6. In vitro drug release studies  
BC membranes were placed in 1.5 ml physiologic solution on 2.0-ml plastic vials and thermostated at 
37 °C. Samples of 500 µl were withdrawn and refilled with an equal volume of fresh buffer at defined 
intervals. Dox concentration was determined by fluorescence as mentioned before. Release 
experiments were performed two times in quadruplicate for each concentration.  
2.7. Cell line and growth conditions  
HT-29 human colon adenocarcinoma cells (HTB-38™) were grown in DMEM containing 10% FBS, 
100 U/ml penicillin and 100 μg/ml streptomycin at 37 °C in 5% CO2 atmosphere. Cells were seeded in 
a 75 cm2 flask and when 70%–80% of confluence was reached, cells were subcultured using 1mL of 
TrypLETM per 25 cm2 flask. For the experiments, cells were grown in multiwell plates. When cells 
reached the desired confluence, the monolayers were washed with DMEM and were incubated under 
different conditions according to the experiments. 
2.8. Cell viability: Crystal violet assay 
A mitogenic bioassay was carried out as described previously with some modifications [25]. Briefly, 
cells were grown in 48-well plates. For the experiments, 3.0 x104 cells/ml were grown for 24 h at 37 
°C. Then, the monolayers were incubated for 24 and 48 h with different concentrations (100–200 μM) 
of free doxorubicin or with the different BC matrices with and without drug (control) for the viability 
assays. After this treatment, the monolayers were washed with PBS and fixed with 5.0% 
glutaraldehyde / PBS at room temperature for 10 min. After that, the cells were stained with 0.5% 
crystal violet / 25% methanol for 10 min. Then, the dye solution was discarded, and the plate was 
10 
 
washed with water and dried. The dye taken up by the cells was extracted using 500 µL/well 100 mM 
glycine/HCl buffer (pH 3.0) / 30% methanol and transferred to test tubes. After a convenient sample 
dilution, the absorbance was read at 540 nm. It was previously shown that under these conditions, the 
colorimetric bioassay strongly correlated with cell proliferation measured by cell counting in 
Neubauer chamber [26]. 
 
3. Results and Discussion 
3.1. Biomaterial characterization 
The thermal properties of native bacterial cellulose (BC), alginate (Alg) and bacterial cellulose-
alginate (BC-Alg) films were investigated by thermogravimetric analysis (Figure 1A). 
Thermogravimetry (TGA) of unmodified bacterial cellulose displayed two decomposition steps in the 
curve. Meanwhile, the weight loss profiles for Alg and BC-Alg were different since they showed a 
three-step curve. The first step was attributed to unbound water content, observed in the temperature 
range between 30 °C and 120 °C. At 180 °C the percentage of weight loss was around 7% for BC, 
18% for Alg and 20% for BC-Alg. The results show higher water content for the hybrid matrix as 
compared to BC membrane because of the alginate high hydrophilicity. It is generally accepted that 
water acts as plasticizer in polymeric matrices [27]. The increase of hydrophilicity in the BC film is 
advantageous since it could be related to the drug loading rise of water-soluble molecules such as 
doxorubicin. 
The second step of BC and BC-Alg samples in the TGA curves was attributed to thermal 
decomposition of the biomaterials (Figure 1A). The decomposition temperature of BC to BC-Alg 
curves shifted down from 350 °C to 300 °C, respectively (Figure 1A). Particularly, the weight loss 
was about 30% in the 200–400 ºC range of BC-Alg films, half of the BC film mass loss in the same 
temperature range (Table I). The high thermal stability of BC-Alg hybrid films compared to that of 
unmodified BC or alginate strongly suggests high interpenetration between both polymers [22,24]. 
This hypothesis was also confirmed by the increase of the maximum thermal degradation temperature 
(Tp) caused by the presence of alginate in cellulose films, because  the Tp is considered a structural 
parameter related to the molecular weight, the crystallinity and the orientation of the polymers [28]. 
The intermediate of TpBC-Alg value between those of both neat biopolymers indicates strong interaction 
between BC fibrils and Alg polymer chains (Table I).  
DTGA analysis of the BC-Alg film showed a small third peak at 650ºC, similar to the peak 
observed for alginate in the range 700–750ºC. Besides, no peak was observed in the same range for the 
BC film samples (Figure 1B). This result confirms the presence of alginate in the network of the BC 
film. Essentially, the thermogravimetric analysis of the BC-Alg scaffold clearly shows strong 
intermolecular interactions between BC and alginate in the hybrid film: the type of molecular 
interactions will be analyzed in the following sections by diffraction (XRD) and spectroscopic 
techniques (ATR-FTIR) 
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The structural properties of bacterial cellulose films containing alginate were studied by XRD 
(Figure 2). The XRD profiles of BC and BC-Alg  show the characteristic Bragg’s angles for both 
matrices at 2θ= 14.6º, 16.9º and 22.8º, which are indexed as (ī 1 0), (0 1 0) and (1 0 0)  reflection 
planes, respectively. The results  revealed the presence of type-1 cellulose crystals in BC films, as  was 
previously reported [29]. The XRD spectra of BC and BC-Alg displayed similar profiles related to the 
peak positions and distributions; those results indicate that the addition of alginate to the bacterial 
culture during the synthesis of the film does not alter the crystalline structure of the bacterial cellulose, 
as previously reported [24]. However, the comparative analysis of both XRD spectra showed two 
major differences associated  with the change in intensity of the (ī 1 0) peak of BC-Alg, which is at 
least 3 times lower than that of BC, and also, the (1 0 0) peak in BC-Alg is wider  than the same peak 
in BC. The results  suggest some changes in the preferential orientation of the (ī 1 0) and (1 0 0) 
planes, as previously reported in BC film supplemented with polyethylene glycol, carboxymethyl- and 
hydroxypropyl cellulose or by complete water removal [29,30]. The changes observed in the BC-Alg 
nanocomposite could be attributed to the interaction between the highly hydroxylated biopolymers 
through hydrogen bridges. The addition of Alg to A. xylinum cultures during the synthesis of BC 
performed in nonstatic cultures decreases the crystallinity index and the crystallite size of the cellulose 
nanocomposite, as shown by XRD analysis. Similarly, the presence of alginate reduces the 
crystallinity index on BC films by about 1.4 times, from 71.0% to 49.7% but with a homogenous 
surface structure, as seen by SEM. Particularly, the reduction of the crystallinity index is generally 
related to an increment in the amorphous phase of films concomitantly with the increased water 
absorption capacity. Drastic reduction of the crystallinity index, attributed to the addition of different 
exogenous molecules, such as Tween 80, urea, Calcofluor White ST, hydroxypropylmethyl and 
carboxymethyl celluloses White ST, to the fermentation culture  affects the synthesis of the bacterial 
cellulose network, as has been previously reported in cultures of Gluconacetobacter xylinum [29]. 
Low BC crystallinity values modified in situ by the addition of 0.04% of alginate to stirred cultures of 
G. xylinum cultures were reported previously [24]. However, the XRD analysis is not conclusive since 
the SEM micrographs showed nonuniform BC-Alg film surfaces with clumps [24]. The SEM images 
indicate an inhomogeneous gel structure that can be attributed to the strategy developed for  cellulose 
production because of stirred culture conditions. Similarly, short cellulose nanofibrils were detected in 
microbial cultures under stirred conditions [21]. Short fibrils increase the randomness structure of 
bacterial cellulose pellicles, reducing the strength and stability of the BC films. Meanwhile, the static 
microbial cultivation method showed long cellulose nanofibrils displaying more structured 
organization of the film at the air–media interface (Figure 3). Additionally, images of both BC and 
BC-Alg show homogenous surfaces but with different characteristics (Figure 3). The BC film surface 
showed a typical bacterial cellulose network composed of long and entangled cellulose nanofibrils 
[31]. On the other hand, the nanocomposite BC-Alg films were homogenous with a more closed 
network. The presence of alginate in static cultures allowed the formation of a strong cooperative 
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network between the biopolymers without clumps, contrary to what was previously reported [24]. Our 
results indicate that the reduction of crystallinity can only be attributed to the strong interconnection of 
the BC fibrils and alginate polymer chains (Figure 3). The main differences between both types of 
BC-Alg nanocomposite surfaces could be attributed to the bacterial cultivation method. 
The BC film surface roughness was reflected by the standard variation of the gray values of the 
selected area (200×300 μm) from the SEM 1,000x micrograph images (Figure 3 A1 and A2). The 
increase of standard variation values is proportional to the roughness of the analyzed surface. The 
analysis of roughness shows a 23% increase in standard deviation for the BC-Alg nanocomposite that 
can be correlated with a highly porous structure of the film network (Figure 1S, Supplementary 
material). The comparative analysis of the means showed that BC-Alg (136.063) is higher than BC 
(114.560), indicating a more regular spatial structure alignment of the biopolymer chains on the 
nanocomposite film due to the presence of alginate. Also, this result indicates the formation of a strong 
cooperative network allowing a more regular structure with the alignment of both types of 
biopolymeric chains. At the same time, BC-Alg films displayed a wide range of gray values, certainly 
due to the formation of an entwined network between  both biopolymers with similar structural and 
chemical characteristics (Figure 1S, Supplementary material).  
Later, the potential interactions between BC and Alg in the nanocomposite were analyzed by FTIR 
(Figure 2S, Supplementary material). The BC film showed peaks centered at 3348 cm-1 and 2890 
cm-1 assigned to O-H and C-H stretching, respectively. Also, peaks centered at 1375 cm-1 and 1033 
cm-1 were observed and assigned to C-H bending and the characteristic vibration for sugar rings, 
respectively [32]. On the other hand, pure alginate showed characteristic peaks centered at 1593 cm-1 
and 1406 cm-1, which are commonly assumed to be asymmetric and symmetric –carboxylic (-COO) 
stretching bands, respectively [33]. However, those characteristic ʋ(-COO)asym and ʋ(-COO)sym 
vibration bands were displaced to 1597 and 1425 cm-1 in BC-Alg hybrid films, respectively. 
Comparison of the -COO vibrations in the spectra showed displacements, especially for ʋ(-COO)sym 
where the band shifted 19 cm-1. Additionally, the O-H and C-H stretchings undergo frequency 
displacement to red and blue values, respectively (Table II). These results could indicate that the 
water bound to the BC film is at least partially replaced by the highly hydrophilic alginate in the 
coacervate scaffold. The observed band shifts in the BC-Alg spectrum could be attributed to the 
intermolecular hydrogen bonds based on the functional groups of alginate and cellulose, rich in 
carboxylate and hydroxyl groups, respectively [20, 24]. The main molecular interactions determined 
by FTIR between both biopolymers clearly suggest high compatibility and the formation of an 
interpenetrating network by a co-gelation mechanism, named Morris model I [29]. These results 
suggest that alginate plays a crucial role in the biophysical properties of the BC matrix. The presence 
of alginate in the BC network exposes more hydrophilic groups that could further increase the film 
hydrophilicity. The increase of hydrophilicity in the BC film is advantageous since it can be related to 
the drug loading rise of water-soluble molecules such as doxorubicin. Doxorubicin is a water-soluble 
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molecule, but its hydrophilicity depends on the environment pH value. It is a weak base, with a 
primary amine group with a pKa of 8.30 [34].  At neutral pH, Dox occurs predominantly in its 
zwitterionic form with positive charge for the amine group and negative charge for the carboxylic 
group [35]. 
The comparative Brunauer–Emmett–Teller (BET) analysis of the films showed an increase of the 
surface area by about 84% and the rise of pore volume by more than 200% from the BC to the BC-Alg 
scaffolds (Table III). Also, the pore size determined by the Barrett–Joyner–Halenda (BJH) model 
showed significant differences between the hybrid and BC films. These changes, which are attributed 
to the presence of a cooperative network of the BC and alginate biopolymers, might contribute to the 
potentiality of the films for Dox entrapment [36,37].  
Therefore, analyses of BC-Alg films by TGA, XRD, FTIR, and SEM showed an intimate contact 
between alginate and cellulose chains, which results in an increase of the BC amorphous film structure 
enhancing the film hydrophilicity. The homogenous characteristic of BC-Alg nanocomposite films is 
relevant and desirable for the development of drug delivery since the molecular release kinetics of the 
cargo can be predictable, modeled and scaled up. 
3.2. Doxorubicin encapsulation  
BC-Alg coacervate films were loaded with doxorubicin  by an absorption mechanism. First, native 
cellulose and hybrid cellulose films were exposed to 3.7 µmols/ml Dox solution. Dox loading was 
about 3 times higher for the BC-Alg than for the BC film (Table IS, Supplementary material), 
attributed to the presence of alginate in the BC network. 
The increase of surface area, pore volume and size of BC-Alg films compared to unmodified BC 
films (Table III) can be correlated with the increase of the drug-film surface interactions and drug 
diffusion from the bulk to the film and consequently, more doxorubicin could be adsorbed and 
entrapped in the hybrid scaffold [38]. In addition, FTIR showed a strong interaction between both 
polymers, BC and Alg, creating a high interpenetrating biopolymeric network that contributes to 
enhanced entrapment and loading capacity of hydrophilic drug molecules such as doxorubicin. On the 
other hand, the ionic interactions of the net negative charges of the carboxylate groups in alginate and 
the positive net charge in Dox molecules could be responsible for enhancing the loading capability in 
the nanocomposite film, as previously reported by our laboratory [19]. Besides, hydroxyl groups of 
cellulose fibers and alginate chains could interact with Dox molecules making hydrogen bonds and 
stabilizing the drug loading in the coacervate film.  
In order to determine the drug loading capacity, BC-Alg films were placed in contact with different 
doxorubicin amounts ranging from 3.7 to 11.0 µmol/ml (Figure 4). A Dox loading of about 10 
µmol/gram of film was found using a drug starting solution containing 3.7 µmol/ml of the drug. 
However, the Dox loading capacity of the BC–Alg films increased linearly (r2= 0.95) when the drug 
concentrations were higher than 3.7 µmol/ml. Particularly, six times more Dox was incorporated into 
the BC-Alg film when the initial drug solution contained 11.0 µmol/ml compared to the solution of 3.7 
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µmol/ml (6:1 ratio). This fact is advantageous since the Dox content in the gel film can be tailored 
based on the patient conditions and therapeutic requirements. 
The low loading capacities for the first initial concentration were attributed only to Dox–matrix 
interactions. Besides, when the drug concentration increased, Dox-Dox interactions  inside the matrix 
became relevant, with a phenomenon commonly described as π–π stacking  taking place [13].  
3.3. Doxorubicin release studies 
BC-Alg films containing different amounts of Dox incubated in PBS buffer showed similar hyperbolic 
kinetic drug release profiles (Figure 5). After burst-size drug release in each case, the percentage of 
Dox release remains almost constant at least for 14 days, but the amount of released drug is not the 
same in each loading case (Table IIS, Supplementary material).  
Dox release from the films could be explained by the existence of different molecular interactions 
between the drug and the film matrix. At low Dox loading, the main interactions between the drug and 
the BC-Alg film could be attributed to ionic and weak electrostatic interactions, as previously reported 
[19]. Meanwhile, at high amount of drug loaded into the film, other interactions such as the - of the 
Dox aromatic ring become more relevant, modifying the drug release profile, similar to what was 
mentioned for the Dox encapsulation mechanism. Finally, a linear relation was found between Dox 
loading and release rates (r2= 0.97), becoming an important parameter for potential personalized 
therapy (Figure 6).  
 
3.4. Cell viability assays 
The cell viability in HT-29 human colorectal adenocarcinoma cell cultures was tested for periods of 24 
and 48 h using the BC-Alg films loaded with 9.55 and 42.25 µmol Dox /g matrix, which  release 76 
µM and 169 µM of drug at 24 h, and 77 µM and 181 µM of drug after 48 h of incubation in PBS, 
respectively. Similarly, controls based on the direct exposure of cells to soluble free Dox in the range  
100–200 µM were assayed under the same experimental conditions. 
Optical and fluorescent microscopy images from the cell cultures after 48 h of incubation were 
taken for systems containing free Dox free (in solution) and Dox released from the BC-Alg films. The 
presence of Dox precipitates was found in both systems (Figure 3S and 4S, Supplementary 
material). However, the Dox crystallite lengths and quantities in the free drug solution were longer 
and bigger than those released from the films. The reduced crystallite amount and size can be analyzed 
considering the effect of the polymer as nucleation agent of the drug and the steric hindrance produced 
by the interpenetrating structure of the BC-Alg film network (Figure 3). Besides, there might be  
diffusional restrictions of Dox to the solution imposed by the film [39,40]. The spectrofluorimetric 
analysis of supernatants containing Dox released from BC-Alg films did not show any shift in 
maximum wavelengths, suggesting the absence of potential complex formation between Dox and 
polymers after drug release that could affect the drug antitumor activity (data not shown). 
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Studies of free Dox tests on cell viability showed very little cell death in the 100–200 µM range of 
drug concentrations after 24 h of exposure. However, about 75% of cell viability was observed in the 
presence of 100 and 150 µM free Dox, which decreased to 63% of viability for 200 µM free Dox after 
48 h (Table IV). Meanwhile, BC-Alg nanocomposite films without Dox payload did not produce any 
cell damage. This result is quite relevant, especially because the BC-Alg biocompatibility assures a 
nontoxic effect on this cell line. Subsequently, cell viability decreased to 59% and 53% in the presence 
of BC-Alg films loaded with 9.55 and 42.25 µmols Dox/g, respectively, after 24 h incubation. 
However, cell viability using BC-Alg films loaded with 9.55 Dox µmols/g was 55% at 48 h but 
without significant differences (p< 0.5) compared to that observed at 24 h. Meanwhile, cell viability 
decreased by 16% (from 53% at 24 h to 37% at 48 h) when the cells were incubated with the BC-Alg 
films containing 42.25 Dox µmol/g (Table IV). Additionally, pictures of cell cultures in DMEM after 
48 h of exposure to free Dox  (100–200 µM) showed a dark red precipitate, suggesting the presence of 
insoluble Dox in the media, but on the contrary, no dark red precipitate was visible to the naked eye 
when Dox was entrapped in the BC-Alg nanocomposite (42.5 µM/g)  
These results clearly indicate a high anticancer effect with Dox loaded into the BC-Alg films 
(Table IV) compared to the free drug. Consequently, the cytotoxic effect of Dox can be modulated by 
the BC-Alg formulation, drug loading quantities and release kinetic conditions. 
 
4. Conclusions 
In the present work, a bacterial nanocellulose scaffold was modified by the incorporation of 
alginate in static cultures by the in situ method, providing a homogeneous biomaterial matrix with 
novel structural properties and keeping the chemotherapeutic agent doxorubicin for long periods of 
time. The performed techniques (TGA, FTIR, SEM) confirmed the alginate and bacterial cellulose 
intimate interaction by weak electrostatic forces, allowing the formation of a strong cooperative 
network with homogeneous increase of the amorphous phase (verified by XRD). The enhancement of 
the amorphous phase led to the exposure of large amounts of hydrophilic groups from alginate within 
the biomaterial environment that might help to improve Dox absorption on the films. Besides, the 
increase of surface area and pore volume enhanced the capacity of the BC-Alg scaffolds for the 
entrapment of Dox molecules. Also, the encapsulation assays demonstrated high Dox load rates in 
comparison with the unmodified bacterial cellulose. The drug loading of the BC-Alg nanocomposite 
scaffolds allows having more than 70 Dox µmols per gram of film. Dox kinetic release profiles of the 
films, obtained with different drug payloads, suggested a linear relationship between the amount of 
drug retained in the matrix and the amount of drug released, giving relevant information about BC-
Alg/Dox interactions. The ability to tailor doxorubicin payload and release may help to define 
personalized therapy for the specific requirements of each patient. 
BC-Alg scaffolds were tested on the colorectal adenocarcinoma cell line. The HT-29 human 
colorectal adenocarcinoma cell was chosen because it is recognized as a relatively Dox-resistant 
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cancer cell line. Direct exposure of the cells to Dox for 24 h showed almost no cell damage, but after 
48 h of exposure, the cell viability decreased to values of around 70%. By comparison, the cells 
exposed to BC-Alg films showed a significant increase in cell damage at both times. Dox 
concentrations were measured from the cell culture supernatants, and similar values to those of free 
Dox experiments were found. Moreover, optical images taken from the supernatants showed that Dox 
released from BC-Alg scaffolds was less prone to form crystallites and consequently precipitation, 
which might be responsible for the decrease in cell toxicity on free Dox assays and the increased 
toxicity of  anthracycline to tumor cells. 
In conclusion, the bacterial cellulose-alginate nanocomposite was successfully developed, showing 
improved properties in terms of interpenetrating biopolymeric network, scaffold homogeneity, and 
ability for sustained release of doxorubicin as an implantable device for cancer treatment. 
In vivo studies against solid tumor models in animals with the BC-Alg nanocomposite containing 
Dox are the next step to determine the potentiality of the scaffold for future biomedical applications in 
anticancer local therapies.  
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Figures 
Figure 1. Thermogravimetic analysis of bacterial cellulose (—), bacterial cellulose-alginate 
nanocomposite (---) and alginate (····). (A) TGA and (B) DTGA curves  
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Figure 2. XRD spectra for bacterial cellulose (BC) and bacterial cellulose-alginate (BC-Alg) 
scaffolds. 
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Figure 3. SEM images from BC scaffolds (A1, B1, C1) and from BC-Alg (A2, B2, C2). Letters: (A) 
1,000X; (B) 5,000X; (C) 10,000X.  
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Figure 4. Entrapment of different starting doxorubicin concentrations in BC-Alg films after 20 h of 
incubation. Dox is expressed in µmol/gram of BC-Alg matrix. Errors bars represent the 
dispersion of the mean of at least three independent experiments. 
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Figure 5. Doxorubicin release profiles from bacterial cellulose-alginate films loaded with different 
quantities of doxorubicin. Symbols of Dox initial loading amount: , 3.7 µmol; , 5.5 
µmol; , 7.4 µmol and , 11.0 µmol. The values are the mean of three replicates (n = 3) 
with standard deviation (SD ≤ 10%). Differences among the data were assessed for 
statistical significance by analysis of variance (ANOVA) with a significance level of 5.0% (p 
< 0.05). 
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Figure 6. Relationship between Dox encapsulation rate and Dox released after 14 days under 
simulated physiologic conditions. 
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Tables 
 
Table I. Relevant values from thermal degradation analysis of native cellulose, hybrid cellulose and 
alginate scaffolds.  
Parameter 
Films 
Cellulose Alginate CB-Alg 
Mass loss in 200-400°C 
range (%) 
67.2 40.6 31.8 
Tp (°C) 345.6 243.0 265.3 
Residue at 750°C (%) 13.5 24.1 29.5 
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Table II. FTIR analysis of bacterial cellulose, alginate and bacterial cellulose-alginate scaffolds. 
 
 
 
 
 
 
 
 
 
 
 
  
BC Alginate BC-Alg Assignments 
(Wavenumbers, cm-1)  
3348 3290 3342 OH stretching 
2890 2929 2942 C–H stretching 
- 1593 1597 asymmetric –COO stretching 
- 1406 1425 symmetric –COO stretching 
1375 - - C–H bending 
1033 1026 1024 C–O–C and C–O–H stretching 
vibration of sugar ring 
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Table III. Adsorption and desorption analysis by BET of bacterial cellulose and bacterial cellulose-
alginate films. 
 
Matrix 
composition 
Surface area 
(m2/g) 
Pore volume 
(cm3/g)* 
Pore size (nm) 
BJH adsorption BET method 
BC 19.97 0.077 22.22 15.10 
BC-Alg 36.76 0.23 27.95 22.11 
* BJH Adsorption cumulative volume of pores between 1.700 nm and 300.000 nm width. 
In all cases standard deviation is lower than 5.0%.  
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Table IV. Viability assays of the HT-29 cell line from human colorectal adenocarcinoma exposed to 
soluble Dox concentrations and BC-Alg films loaded with Dox (9.55 and 42.25 µmol/g ) 
after 24 and 48 h of incubation. Mean ± s.e.m. of 3 independent experiments. 
System 
Soluble Doxorubicin 
(µM) 
Cell Viability (%) 
24 hours 48 hours 
Free  
100 94.0 ± 3.7 74.0 ± 2.7 
150 93.0 ± 3.3 73.0 ± 2.7 
200 95.0 ± 2.7 63.0 ± 2.1 
 
 
 
 
BC-Alg 
Encapsulated 
Dox (µmol/g) 
Dox release (µM) Cell Viability (%) 
24 hours 48 hours 24 hours 48 hours 
- - -  103.0 ± 3.1  97.4 ± 2.1 
9.55 ± 1.87 76.0 ± 5.0 169.0 ±5.0 59.0 ± 7.2 55.0 ± 8.2 
42.25 ± 3.15 77.0 ± 5.0 181.0 ± 8.0 53.0 ± 1.6 37.0 ± 0.5 
 
 
